MedTrace Logo

Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

NCT03663283 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine if peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine will prolong the duration of block, improve pain scores, and decrease opioid utilization in the post-operative period when compared to peripheral nerve block with standard bupivacaine alone.

Conditions

  • Arthropathy Shoulder

Interventions

DRUG

Liposomal Bupivacaine

Interscalene Nerve Blocks

DRUG

Bupivacaine Hydrochloride

Interscalene Nerve Blocks

Sponsors & Collaborators

Principal Investigators

  • Steven J Hattrup · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-29
Primary Completion
2020-02-14
Completion
2020-02-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03663283 on ClinicalTrials.gov